| 282.67 0.19 (0.07%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 341.07 | 1-year : | 398.38 |
| Resists | First : | 292.01 | Second : | 341.07 |
| Pivot price | 278.35 |
|||
| Supports | First : | 272.58 |
Second : | 260.57 |
| MAs | MA(5) : | 280.64 |
MA(20) : | 275.91 |
| MA(100) : | 266.97 |
MA(250) : | 257.8 |
|
| MACD | MACD : | 4.8  |
Signal : | 4.8 |
| %K %D | K(14,3) : | 65.9 |
D(3) : | 61.1 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 292.93 | Low : | 207.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LH ] has closed below upper band by 29.2%. Bollinger Bands are 7.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 285 - 286.1 | 286.1 - 287.19 |
| Low: | 276.08 - 277.4 | 277.4 - 278.73 |
| Close: | 280.54 - 282.56 | 282.56 - 284.58 |
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Fri, 20 Feb 2026
Labcorp Holdings Inc. $LH Shares Bought by Persistent Asset Partners Ltd - MarketBeat
Thu, 19 Feb 2026
Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Thu, 19 Feb 2026
Labcorp Holdings Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Wed, 18 Feb 2026
Labcorp Holdings Inc. (NYSE:LH) Q4 2025 Earnings Call Transcript - Insider Monkey
Tue, 17 Feb 2026
Morgan Stanley Maintains Overweight on Labcorp Holdings Inc. (LH) Feb 17, 2026 - Meyka
Tue, 17 Feb 2026
Labcorp Holdings Inc (LH) Q4 2025 Earnings Call Highlights: Stro - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Equipment & Services
|
|
| Shares Out | 83 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 98.6 (%) |
| Shares Short | 3,030 (K) |
| Shares Short P.Month | 3,150 (K) |
| EPS | 10.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 104.77 |
| Profit Margin | 6.2 % |
| Operating Margin | 11.3 % |
| Return on Assets (ttm) | 4.6 % |
| Return on Equity (ttm) | 10.1 % |
| Qtrly Rev. Growth | 8.6 % |
| Gross Profit (p.s.) | 47.28 |
| Sales Per Share | 166.1 |
| EBITDA (p.s.) | 23.64 |
| Qtrly Earnings Growth | 56 % |
| Operating Cash Flow | 1,800 (M) |
| Levered Free Cash Flow | 1,120 (M) |
| PE Ratio | 27.55 |
| PEG Ratio | 0 |
| Price to Book value | 2.69 |
| Price to Sales | 1.7 |
| Price to Cash Flow | 13.01 |
| Dividend | 0.72 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|